Biotech

BioHarvest Sciences Inc. ("BioHarvest" or the "Company") (CSE: BHSC) announces that it has issued a total 5,693,800 incentive stock options. 1,350,000 incentive stock options were granted to employees and consultants and 4,343,800 to the Company's Chairman Zaki Rakib. The stock options granted are exercisable to purchase a common share of the Company at a price of $0.32 per share for a term of 10 years.

1,300,00 stock options granted will vest quarterly over a 3-year period, and 4,393,800 will vest quarterly over one year.

About BioHarvest Sciences Inc.

BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing Biotech firm listed on the Canadian Securities Exchange. BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at industrial scale, without the need to grow the plant itself. This technology is economical, ensures consistency, and avoids the negative environmental impacts associated with traditional agriculture. BioHarvest is currently focused on nutraceuticals and the medicinal cannabis markets. Visit: www.bioharvest.com.

BioHarvest Sciences Inc.

Ilan Sobel, Chief Executive Officer

For further information, please contact:

Dave Ryan, VP Investor Relations & Director

Phone: 1 (604) 622-1186

Email: dave@bioharvest.com

Forward-Looking Statements

Information set forth in this news release includes forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance that we will achieve our objective of being a leading supplier of Cannabis. Delays and cost overruns may result in delays achieving our objectives. Projected sales of Cannabis will require the company to obtain production and / or export licensing which cannot be assured.

All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

Source

Click here to connect with BioHarvest Sciences Inc. (CSE: BHSC) , to receive an Investor Presentation

BHSC:CNX
BioHarvest Sciences to Webcast Live at VirtualInvestorConferences.com September 15th

BioHarvest Sciences to Webcast Live at VirtualInvestorConferences.com September 15th

Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com

BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE:8MV), a biotechnology company focused on growing plant cells without the plant via its patented CELLicitation platform, today announced that Ilan Sobel, Chief Executive Officer, will present live at VirtualInvestorConferences.com on September 15, 2022.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Life Sciences Virtual Investor Conference Agenda Announced for September 15th

Life Sciences Virtual Investor Conference Agenda Announced for September 15th

Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Life Sciences Virtual Investor Conference to be held on September 15 th .

Individual investors, institutional investors, advisors, and analysts are invited to attend this virtual event showcasing live executive presentations from companies addressing worldwide opportunities in the life sciences.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Business Intelligence Group Awards BioHarvest Sciences with the Prestigious Sustainability Leadership Award

Business Intelligence Group Awards BioHarvest Sciences with the Prestigious Sustainability Leadership Award

  • The award recognizes the sustainability impact of BioHarvest's Bio Plant CELLicitation technology, which enables industrial production of plant metabolites without growing the plant itself
  • BioHarvest Sciences receives the award with other industry thought leaders such as AstraZeneca, Agilent, and Honeywell

Cannot view this image? Visit: https://images.newsfilecorp.com/files/6168/136029_b77540d5d49ee908_002.jpg

Figure 1

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/6168/136029_b77540d5d49ee908_002full.jpg

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
BioHarvest Sciences Inc. Launches First Major United States Marketing Campaign

BioHarvest Sciences Inc. Launches First Major United States Marketing Campaign

BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) ("BioHarvest" or "the Company") has announced the first multimedia campaign for VINIA™ in the USA, Phase 1. The company is scaling up its US marketing in line with a 2022 growth plan that aims for significant growth in sales orders following commercial entry in 2021.

"We are delighted to launch our first integrated marketing campaign aimed at expanding our loyal customer base here in the USA," said CEO Ilan Sobel, in New York for the launch. "Bringing our new 20 Ton production facility online was integral to scaling global VINIA™ supply, so this marketing launch is testament to the entire VINIA™ team's coordinated dedication to making it happen."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
BioHarvest Sciences Inc. Commences Trading on the OTCQB Market

BioHarvest Sciences Inc. Commences Trading on the OTCQB Market

BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) ("BioHarvest" or "the Company") ") is pleased to announce that its common shares are now trading on the OTCQB® Venture Market under the ticker symbol "CNVCF".

"Admission to the OTCQB® market is an important step to increase US investor access to BioHarvest Sciences, and it provides US investors an additional level of transparency as we expand both our investor base and our customer base in North America." Stated CEO Ilan Sobel. "We will continue to work on expanding our global visibility to investors to match the commercial entry of our products into new markets."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

AMGEN OPENS NEW STATE-OF-THE-ART RESEARCH AND DEVELOPMENT LABORATORY SITE IN SAN FRANCISCO BAY AREA

245,000 Square Foot Lab Demonstrates Amgen's Continued Commitment to Innovation

Oct. 6, 2022 ) Amgen (NASDAQ:AMGN) today announced the opening of a new research and development site in San Francisco's Oyster Point, continuing the company's nearly two-decade presence in the region. The new site will constitute the company's second largest research and development facility, which focuses on discovering therapeutics for patients living with cancer, inflammatory disease and cardiometabolic disorders.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
different multicolored pills

How to Invest in Biotechnology (Updated 2022)

Investors interested in the life science sector are well aware of the importance of biotechnology.

From finding cures for diseases to feeding future generations, many areas of day-to-day life are influenced by players in the biotechnology space, and expert projections show the industry's future looks bright.

But how can investors gain exposure to biotechnology? Here’s a brief overview of how to invest in the expanding biotechnology market, from stocks to watch to exchange-traded funds (ETFs).

Keep reading...Show less

AbbVie to Host Third-Quarter 2022 Earnings Conference Call

ABBVie (NYSE: ABBV) will announce its third-quarter 2022 financial results on Friday, October 28, 2022 before the market opens. ABBVie will host a live webcast of the earnings conference call at 8 a.m. CT . It will be accessible through ABBVie's Investor Relations website investors.ABBVie.com . An archived edition of the session will be available later that day.

About AbbVie

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Autolus Therapeutics Announces Collaboration with Bristol Myers Squibb for Use of Autolus' Proprietary Safety Switch System

- Bristol Myers Squibb to receive access to Autolus' RQR8 safety switch for use in cell therapy programs -

- Autolus to receive an upfront payment, with potential for near term option exercise fees and development milestone payments plus royalties -

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Kite Receives U.S. FDA Approval of Viral Vector Manufacturing Facility in Southern California to Produce Commercial Product

-- Viral Vector Facility Further Strengthens Vertical Integration of Kite's Global CAR T-cell Therapy Manufacturing Network, Supports Growing Demand of Company's Blood Cancer Treatments --

-- Kite is the Only Cell Therapy Company with In-House Viral Vector Manufacturing Capabilities for Both Commercial Products and Clinical Trials --

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Cardiol Therapeutics Announces Pre-Clinical Study Results Demonstrating CardiolRx Inhibits and also Promotes Reversal of Mechanisms Leading to Cardiac Fibrosis

Cardiol Therapeutics Announces Pre-Clinical Study Results Demonstrating CardiolRx Inhibits and also Promotes Reversal of Mechanisms Leading to Cardiac Fibrosis

Data Presented at The Annual Scientific Meeting of the Heart Failure Society of America September 30th, 2022

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of cardiovascular diseases ("CVD"), announced today that study results demonstrate the active pharmaceutical ingredient ("API") in CardiolRx™ inhibits and also promotes the reversal of mechanisms known to play a role in the occurrence and development of fibrotic CVD. The data were presented by its research collaborators from Houston Methodist DeBakey Heart & Vascular Center at The Annual Scientific Meeting of the Heart Failure Society of America ("HFSA2022").

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×